Compare AMETEK, Inc. (AME) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AMETEK, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? AMETEK, Inc. trades at $232.93 (market cap $53.63B), while Recursion Pharmaceuticals Inc trades at $3.51 (market cap $1.89B). The key difference: AMETEK, Inc. is far larger — about 28.4× Recursion Pharmaceuticals Inc's market cap, and AMETEK, Inc. pays a 0.58% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AME | RXRX | |
|---|---|---|
Market Cap | $53.63B | $1.89B |
Sector | Industrials | Health |
52-Week High | $241.94 | $6.79 |
52-Week Low | $176.44 | $2.84 |
Enterprise Value | $55.33B | $1.31B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $233.98, up 0.42% today, with a neutral technical signal and strong fundamentals including three consecutive quarterly EPS beats. The company maintains robust profitability with a 20.11% net margin and recently completed the acquisition of First Aviation Services, expanding its aerospace and defense footprint. Cash flow remains positive with $83.95M net inflow in 2025.
Outlook is positive with a $260 consensus price target representing 11% upside, supported by 68.97% analyst buy ratings. Risks include elevated P/E of 35.34 and integration challenges from recent acquisitions. The stock offers growth exposure to industrial technology and aerospace sectors with stable dividend payments.
RXRX trades at $3.56, down 5.32% today, with a bullish technical signal from moving averages but concerning fundamentals. The company shows deep losses with a -851.51% net income margin and negative cash flow from operations, though it has beaten earnings estimates for three consecutive quarters. Analyst consensus is mixed with a $7.83 price target representing significant upside potential from current levels.
While technical indicators suggest near-term strength and analyst targets imply 120% upside, RXRX faces substantial execution risks as a pre-revenue biotech. The company's AI-driven drug discovery platform shows promise but requires successful clinical outcomes to justify its valuation. High cash burn and negative profitability metrics present significant challenges for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
